LONG MINI-FUTURE - REGENERON PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 14:02:29 2024-06-14 EDT | ||
| 5.07 EUR | +2.42% |
|
| Current month | +13.93% | ||
| 1 month | +11.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about REGENERON PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 5.07 | +2.42% |
| 24-06-13 | 4.95 | +1.02% |
| 24-06-12 | 4.9 | +0.41% |
| 24-06-11 | 4.88 | +2.95% |
| 24-06-10 | 4.74 | -1.04% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 02:02 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | REGENERON PHARMACEUTICALS, INC. |
| Issuer | 
Vontobel
|
| WKN | VQ2AQ1 |
| ISIN | DE000VQ2AQ13 |
| Date issued | 2020-12-07 |
| Strike | 493.6 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.08 € |
|---|---|
| Lowest since issue | 0.36 € |
Company Profile
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
Ratings for Regeneron Pharmaceuticals, Inc.
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Regeneron Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,037
USD
Average target price
1,047
USD
Spread / Average Target
+1.04%
- Stock Market
- Certificates
- Certificat
